{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:16Z","timestamp":1793018116160,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01940-6","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:50Z","timestamp":1790882450000},"page":"5595-5617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4009-0544","authenticated-orcid":false,"given":"Costanza","family":"Falcidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9859-4475","authenticated-orcid":false,"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1438-9553","authenticated-orcid":false,"given":"Ruggero","family":"Cascio Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6269-448X","authenticated-orcid":false,"given":"Angela","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-8581","authenticated-orcid":false,"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"1940_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195633","volume":"11","author":"G Pappa","year":"2022","unstructured":"Pappa G, Sgouros D, Theodoropoulos K, Kanelleas A, Bozi E, Gregoriou S, et al. The IL-4\/-13 axis and its blocking in the treatment of atopic dermatitis. J Clin Med. 2022;11:5633. https:\/\/doi.org\/10.3390\/jcm11195633.","journal-title":"J Clin Med"},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ad.2020.04.009","volume":"111","author":"JM Carrascosa","year":"2020","unstructured":"Carrascosa JM, Morillas-Lahuerta V. Comorbilidades en dermatitis at\u00f3pica: actualizaci\u00f3n y controversias. Actas Dermo-Sifiliogr. 2020;111:481\u20136. https:\/\/doi.org\/10.1016\/j.ad.2020.04.009.","journal-title":"Actas Dermo-Sifiliogr"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409\u201331. https:\/\/doi.org\/10.1111\/jdv.18345.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR5","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema\u2014part II\u202f: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36:1904\u201326. https:\/\/doi.org\/10.1111\/jdv.18429.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"2576134","DOI":"10.1080\/09546634.2025.2576134","volume":"36","author":"E Rodrigues","year":"2025","unstructured":"Rodrigues E, Domingues J, Alvarenga JM, Chovatiya R, Torres T. Nemolizumab for the treatment of atopic dermatitis. J Dermatol Treat. 2025;36:2576134. https:\/\/doi.org\/10.1080\/09546634.2025.2576134.","journal-title":"J Dermatol Treat"},{"key":"1940_CR7","unstructured":"European Medicines Agency. Olumiant: EPAR\u2014Product Information [Internet]. Amsterdam: European Medicines Agency; 2017 Mar 16 [updated 2026 May 7; cited 2026 Jul 4]. [Internet]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed 4 Jul 2026."},{"key":"1940_CR8","unstructured":"European Medicines Agency. Rinvoq: EPAR \u2013 Product Information [Internet]. Amsterdam: European Medicines Agency; 2019 Dec 18 [updated 2026 Jun 22; cited 2026 Jul 4]. [Internet]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq. Accessed 4 Jul 2026."},{"key":"1940_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2020-8-5","volume":"9","author":"N Nezamololama","year":"2020","unstructured":"Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9:1\u20137. https:\/\/doi.org\/10.7573\/dic.2020-8-5.","journal-title":"Drugs Context"},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Burroni AG, Chiricozzi A, Dapavo P, et al. Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus. Dermatol Ther. 2024;14:919\u201332. https:\/\/doi.org\/10.1007\/s13555-024-01135-x.","journal-title":"Dermatol Ther"},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour J-P, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate\u2010to\u2010severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242\u201355. https:\/\/doi.org\/10.1111\/bjd.18898.","journal-title":"Br J Dermatol"},{"key":"1940_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85:62\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.028.","journal-title":"J Am Acad Dermatol"},{"key":"1940_CR14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","volume":"157","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157:691. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1273.","journal-title":"JAMA Dermatol"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/jdv.18816","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Werfel T, Cardillo TE, Colvin S, et al. Long\u2010term efficacy (up to 68 weeks) of baricitinib in combination with topical corticosteroids in adult patients with moderate\u2010to\u2010severe atopic dermatitis: analysis of treatment responders, partial responders and nonresponders originating from study BREEZE\u2010AD7. J Eur Acad Dermatol Venereol. 2023;37:1036\u201345. https:\/\/doi.org\/10.1111\/jdv.18816.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1080\/09546634.2020.1839008","volume":"33","author":"K Reich","year":"2022","unstructured":"Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatol Treat. 2022;33:1521\u201330. https:\/\/doi.org\/10.1080\/09546634.2020.1839008.","journal-title":"J Dermatol Treat"},{"key":"1940_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260.","journal-title":"JAMA Dermatol"},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, De Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"key":"1940_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157:1047. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40257-025-00975-3","volume":"26","author":"AD Irvine","year":"2025","unstructured":"Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results through 140 weeks. Am J Clin Dermatol. 2025;26:1003\u201316. https:\/\/doi.org\/10.1007\/s40257-025-00975-3.","journal-title":"Am J Clin Dermatol"},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, Chu C-Y, Hong HC, Katoh N, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158:404. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0029.","journal-title":"JAMA Dermatol"},{"key":"1940_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092953","volume":"14","author":"L Ibba","year":"2025","unstructured":"Ibba L, Falcidia C, Di Giulio S, Bianco M, Valenti M, Facheris P, et al. Real-world effectiveness and safety of upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 52-week retrospective study. J Clin Med. 2025;14:2953. https:\/\/doi.org\/10.3390\/jcm14092953.","journal-title":"J Clin Med"},{"key":"1940_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cea.70125","volume":"55","author":"Y Kim","year":"2025","unstructured":"Kim Y, Seo G, Koopman JJE, Yee J. Real\u2010world effectiveness and safety of JAK inhibitors in atopic dermatitis: a systematic review and meta\u2010analysis. Clin Exp Allergy. 2025;55:755\u201372. https:\/\/doi.org\/10.1111\/cea.70125.","journal-title":"Clin Exp Allergy"},{"key":"1940_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40257-025-00997-x","volume":"27","author":"ATM R\u00f8nnstad","year":"2026","unstructured":"R\u00f8nnstad ATM, Isufi D, Bunick CG, Chovatiya R, Nielsen M-L, Alinaghi F, et al. Real-world evidence of effectiveness and safety of abrocitinib, baricitinib and upadacitinib in atopic dermatitis: a systematic review and meta-analysis. Am J Clin Dermatol. 2026;27:49\u201366. https:\/\/doi.org\/10.1007\/s40257-025-00997-x.","journal-title":"Am J Clin Dermatol"},{"key":"1940_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2578249","volume":"36","author":"N Gori","year":"2025","unstructured":"Gori N, Di Nardo L, Ippoliti E, Antonelli F, Boeti L, Balato A, et al. Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors. J Dermatol Treat. 2025;36:2578249. https:\/\/doi.org\/10.1080\/09546634.2025.2578249.","journal-title":"J Dermatol Treat"},{"key":"1940_CR27","doi-asserted-by":"publisher","first-page":"adv00820","DOI":"10.2340\/actadv.v102.3978","volume":"102","author":"CM Boesjes","year":"2022","unstructured":"Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay registry. Acta Derm Venereol. 2022;102:adv00820. https:\/\/doi.org\/10.2340\/actadv.v102.3978.","journal-title":"Acta Derm Venereol"},{"key":"1940_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-025-01373-7","volume":"15","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Schadeck T, Jacobs F, Weyergraf A, Mortazawi D, Hagemann T, et al. Early achievement of high treatment targets in moderate-to-severe atopic dermatitis with upadacitinib: real-world evidence from the observational UP-TAINED study. Dermatol Ther. 2025;15:919\u201331. https:\/\/doi.org\/10.1007\/s13555-025-01373-7.","journal-title":"Dermatol Ther"},{"key":"1940_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaad.2025.01.052","volume":"92","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus\u2014experienced patients. J Am Acad Dermatol. 2025;92:1049\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.052.","journal-title":"J Am Acad Dermatol"},{"key":"1940_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13555-024-01334-6","volume":"15","author":"S Gregoriou","year":"2025","unstructured":"Gregoriou S, Koumprentziotis I-A, Kleidona IA, Bakakis M, Hatzidimitriou E, Douvali T, et al. Successful achievement of demanding outcomes in upadacitinib-treated atopic dermatitis patients: a real-world, 96-week single-centre study. Dermatol Ther. 2025;15:227\u201335. https:\/\/doi.org\/10.1007\/s13555-024-01334-6.","journal-title":"Dermatol Ther"},{"key":"1940_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/jdv.19581","volume":"38","author":"AR Schl\u00f6sser","year":"2024","unstructured":"Schl\u00f6sser AR, Boeijink N, Olydam J, Nijsten TEC, Hijnen D. Upadacitinib treatment in a real\u2010world difficult\u2010to\u2010treat atopic dermatitis patient cohort. J Eur Acad Dermatol Venereol. 2024;38:384\u201392. https:\/\/doi.org\/10.1111\/jdv.19581.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR32","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jaad.2023.08.059","volume":"89","author":"JR Georgakopoulos","year":"2023","unstructured":"Georgakopoulos JR, Sheka D, Rankin B, Maliyar K, Rimke A, Prajapati VH, et al. Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: a multicenter retrospective study. J Am Acad Dermatol. 2023;89:1308\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.059.","journal-title":"J Am Acad Dermatol"},{"key":"1940_CR33","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.41504","volume":"105","author":"AR Schlosser","year":"2025","unstructured":"Schlosser AR, Nijman L, Schappin R, Nijsten TEC, Hijnen D. Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice. Acta Derm Venereol. 2025;105:adv41504. https:\/\/doi.org\/10.2340\/actadv.v105.41504.","journal-title":"Acta Derm Venereol"},{"key":"1940_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20581","author":"T Torres","year":"2025","unstructured":"Torres T, Yeung J, Prajapati V, Ribero S, Balato A, Valerio Marzano A, et al. Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study. J Eur Acad Dermatol Venereol [Internet]. 2025. https:\/\/doi.org\/10.1111\/jdv.20581.","journal-title":"J Eur Acad Dermatol Venereol [Internet]"},{"key":"1940_CR35","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M Bruin-Weller","year":"2021","unstructured":"Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101:adv00402. https:\/\/doi.org\/10.2340\/00015555-3751.","journal-title":"Acta Derm Venereol"},{"key":"1940_CR36","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22:662\u201380. https:\/\/doi.org\/10.1038\/s41573-023-00735-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1940_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/jdv.70378","volume":"40","author":"L Gargiulo","year":"2026","unstructured":"Gargiulo L, Narcisi A. Sustained control in atopic dermatitis: are we approaching disease modification? J Eur Acad Dermatol Venereol. 2026;40:726\u20137. https:\/\/doi.org\/10.1111\/jdv.70378.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/jdv.70165","volume":"40","author":"M Gooderham","year":"2026","unstructured":"Gooderham M, Ameen M, Hong HC, Katoh N, Langley RG, Peris K, et al. Efficacy of up to 4 years of tralokinumab in adults with moderate\u2010to\u2010severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2026;40:876\u201386. https:\/\/doi.org\/10.1111\/jdv.70165.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20699","author":"L Gargiulo","year":"2025","unstructured":"Gargiulo L, Ferrucci SM, Ibba L, Ingurgio RC, Alfano A, Amoruso GF, et al. Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study. J Eur Acad Dermatol Venereol [Internet]. 2025. https:\/\/doi.org\/10.1111\/jdv.20699.","journal-title":"J Eur Acad Dermatol Venereol [Internet]"},{"key":"1940_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/ddg.15688","volume":"23","author":"H Wu","year":"2025","unstructured":"Wu H, Zhu J, Yang N, Ji X, Li Z, Zhou Y, et al. Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. JDDG J Dtsch Dermatol Ges. 2025;23:702\u201310. https:\/\/doi.org\/10.1111\/ddg.15688.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1940_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60:44\u20137. https:\/\/doi.org\/10.2340\/00015555924447.","journal-title":"Acta Derm Venereol"},{"key":"1940_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1365-2133.2007.08412.x","volume":"158","author":"EEA Brenninkmeijer","year":"2008","unstructured":"Brenninkmeijer EEA, Schram ME, Leeflang MMG, Bos JD, Spuls PhI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158:754\u201365. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08412.x.","journal-title":"Br J Dermatol"},{"key":"1940_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-017-0299-4","volume":"19","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol. 2018;19:15\u201322. https:\/\/doi.org\/10.1007\/s40257-017-0299-4.","journal-title":"Am J Clin Dermatol"},{"key":"1940_CR44","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/bjd\/ljae346","volume":"192","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, et al. Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2025;192:247\u201360. https:\/\/doi.org\/10.1093\/bjd\/ljae346.","journal-title":"Br J Dermatol"},{"key":"1940_CR45","doi-asserted-by":"publisher","first-page":"adv14153","DOI":"10.2340\/actadv.v103.14153","volume":"103","author":"Z Reguiai","year":"2023","unstructured":"Reguiai Z, Becherel PA, Perrot JL, Fougerousse AC, Begon E, Poreaux C, et al. Impact of baricitinib on patients\u2019 quality-of-life after one year of treatment for atopic dermatitis in real-world practice: results of the observatory of chronic inflammatory skin diseases registry. Acta Derm Venereol. 2023;103:adv14153. https:\/\/doi.org\/10.2340\/actadv.v103.14153.","journal-title":"Acta Derm Venereol"},{"key":"1940_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","volume":"25","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, et al. Early and sustained improvements in symptoms and quality-of-life with upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: 52-week results from two phase III randomized clinical trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol. 2024;25:485\u201396. https:\/\/doi.org\/10.1007\/s40257-024-00853-4.","journal-title":"Am J Clin Dermatol"},{"key":"1940_CR47","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s13555-025-01469-0","volume":"15","author":"JI Silverberg","year":"2025","unstructured":"Silverberg JI, Gooderham M, Wollenberg A, Pink AE, Ruiz Dasilva D, Kwatra SG, et al. Impact of achieving optimal treatment targets and minimal disease activity on health-related quality-of-life and satisfaction in patients with atopic dermatitis. Dermatol Ther. 2025;15:2255\u201373. https:\/\/doi.org\/10.1007\/s13555-025-01469-0.","journal-title":"Dermatol Ther"},{"key":"1940_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2026.2665961","volume":"37","author":"EL Simpson","year":"2026","unstructured":"Simpson EL, Prajapati VH, Bunick CG, Chovatiya R, Gold LFS, Figueras Nart I, et al. Long-term benefits of upadacitinib for atopic dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials. J Dermatol Treat. 2026;37:2665961. https:\/\/doi.org\/10.1080\/09546634.2026.2665961.","journal-title":"J Dermatol Treat"},{"key":"1940_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/medicina62061127","volume":"62","author":"C Falcidia","year":"2026","unstructured":"Falcidia C, D\u2019Oria F, Foggi G, Facheris P, Bianco M, Ibba L, et al. Dose adjustment of JAK inhibitors for the management of moderate-to-severe atopic dermatitis: a single-centre retrospective study. Medicina (Mex). 2026;62:1127. https:\/\/doi.org\/10.3390\/medicina62061127.","journal-title":"Medicina (Mex)"},{"key":"1940_CR50","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman\u2010Yassky","year":"2023","unstructured":"Guttman\u2010Yassky E, Silverberg JI, Tha\u00e7i D, Papp KA, St\u00e4nder S, Beck LA, et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate\u2010to\u2010severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37:2558\u201368. https:\/\/doi.org\/10.1111\/jdv.19391.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR51","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bjd\/ljac057","volume":"188","author":"K Reich","year":"2023","unstructured":"Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, et al. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol. 2023;188:208\u201317. https:\/\/doi.org\/10.1093\/bjd\/ljac057.","journal-title":"Br J Dermatol"},{"key":"1940_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86:104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"key":"1940_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01038-x","author":"L Rapparini","year":"2026","unstructured":"Rapparini L, Starace M, Apalla Z, El Barch M, Delpuech A, Baali S, et al. Dermatologic toxicities induced by JAK inhibitors. Am J Clin Dermatol. 2026. https:\/\/doi.org\/10.1007\/s40257-026-01038-x.","journal-title":"Am J Clin Dermatol"},{"key":"1940_CR54","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35:476\u201385. https:\/\/doi.org\/10.1111\/jdv.16948.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR55","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies. J Allergy Clin Immunol. 2023;151:172\u201381. https:\/\/doi.org\/10.1016\/j.jaci.2022.09.023.","journal-title":"J Allergy Clin Immunol"},{"key":"1940_CR56","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.20674","volume":"39","author":"LF Van Der Gang","year":"2025","unstructured":"Van Der Gang LF, Atash K, Zuithoff NPA, Haeck I, Boesjes CM, Baco\u015f\u2010Cosma OI, et al. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. J Eur Acad Dermatol Venereol. 2025;39:2056\u201368. https:\/\/doi.org\/10.1111\/jdv.20674.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim H, Kim B, Kim M, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta\u2010analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38:52\u201361. https:\/\/doi.org\/10.1111\/jdv.19426.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1940_CR58","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00228-022-03400-4","volume":"78","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Batel Marques F. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2022;78:1923\u201333. https:\/\/doi.org\/10.1007\/s00228-022-03400-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"1940_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01867-y","author":"P Facheris","year":"2026","unstructured":"Facheris P, Gargiulo L, Ibba L, Valenti M, D\u2019Oria F, Foggi G, et al. JAK inhibitor safety in atopic dermatitis and alopecia areata: a 4.5-year real-world retrospective cohort study. Dermatol Ther. 2026. https:\/\/doi.org\/10.1007\/s13555-026-01867-y.","journal-title":"Dermatol Ther"},{"key":"1940_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, Su\u00e1rez-Fari\u00f1as M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01940-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:05:18Z","timestamp":1793016318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01940-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01940-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"13 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Francesco D\u2019Oria, Costanza Falcidia, Giulio Foggi, and Angela Alfano have nothing to declare. Matteo Bianco has served as a speaker for BMS. Luciano Ibba has been a consultant and\/or speaker and has served as an advisory board member for Almirall and LEO Pharma. Ruggero Cascio Ingurgio has served as a consultant for UCB Pharma. Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB and Difa Cooper. Mario Valenti is an Editorial Board Member of Dermatology and Therapy. Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Luigi Gargiulo has been a consultant and\/or speaker and has participated in advisory boards for AbbVie, Almirall, Amgen, BMS, Eli Lilly, Incyte, Galderma, Pierre Fabre, Johnson and Johnson, Novartis, Pfizer, Sanofi, and UCB Pharma.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was exempted because the study was retrospective and did not deviate from standard clinical practice. All patients received baricitinib or upadacitinib in accordance with good clinical practice and current European guidelines. For a subset of patients, upadacitinib was supplied by AbbVie through a Compassionate Use Program activated pursuant to the Italian Ministerial Decree of 7 September 2017. All included patients had provided written informed consent for the retrospective use of data collected during routine clinical care, including demographic and clinical information. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments, and data collection and handling complied with applicable regulations regarding patient protection and privacy.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}